Protective heterologous T cell immunity in COVID-19 induced by the trivalent MMR and Tdap vaccine antigens
Vijayashree Mysore(Kala Pharmaceuticals (United States)), Tanya N. Mayadas(University of North Carolina at Chapel Hill), Michaël Desjardins(Centre Hospitalier de l’Université de Montréal), Xinge Ji(Cleveland Clinic), Tal Gilboa(Brigham and Women's Hospital), Michael W. Kattan(Unknown), Xavier Culleré(Brigham and Women's Hospital), Matthew L. Settles(University of California, Davis), Blythe Durbin‐Johnson(University of California, Davis), David R. Walt(Brigham and Women's Hospital), Lindsey R. Baden(Brigham and Women's Hospital), Andrew H. Lichtman(Brigham and Women's Hospital), Lara Jehi(Cleveland Clinic Lerner College of Medicine)
Cited by 54
Related Papers
Assessing the Performance of Prediction Models
|Epidemiology|2009|4.9k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k